Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Expanding US operations to address the increased demand for API development and manufacturing
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
Subscribe To Our Newsletter & Stay Updated
